Evidera
Asim Priyendu, PhD has a diverse work experience in the pharmaceutical and healthcare industry. Asim started their career as a Medical Business Associate at Glaxo Smith Kline in 2012. Asim then worked as a Research Fellow at Manipal College of Pharmaceutical Sciences from 2012 to 2015. In 2016, they joined Indegene as a Senior Analyst and later transitioned to Cactus Communications as a Senior Medical Writer. In 2019, Asim joined Eli Lilly and Company as a Senior Associate Manager. Asim then worked at Parexel as a Manager-HEOR from 2020 to 2021. Currently, Asim is working at Evidera, starting as a Senior Manager and later promoted to the role of Associate Director-GSPD Thermo Fisher Scientific in 2022.
Asim Priyendu, PhD, completed their education at Manipal Academy of Higher Education. Asim obtained their Bachelor's Degree in Pharmacy from 2006 to 2010. Asim then pursued a Master's Degree in Pharmacy, Pharmaceutical Sciences, and Administration, which they completed from 2010 to 2012. Subsequently, they pursued a Doctor of Philosophy (Ph.D.) degree with a focus on Pharmacoeconomics/Pharmaceutical Economics and Antibiotic Resistance in ICU patients, which they obtained from 2013 to 2019.
In addition to their formal education, Asim Priyendu has also obtained several certifications. Asim completed courses on Budget Impact Analysis I & II, Introduction to Modelling Methods, and Modeling: Design and structure of a model from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in May 2016. Asim also completed a Certificate Course in Biostatistics, Epidemiology, and Research Methodology from the Department of Statistics, Manipal University in June 2013. Additionally, they completed a General Course on Intellectual Property from the World Intellectual Property Organization in November 2012.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.